Clinically relevant drug interactions with antiepileptic drugs

British Journal of Clinical Pharmacology

Volumn 61, Issue 3, 2006, Pages 246-255

  Perucca, Emilio ^a,b  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antiepileptic drugs; Drug interactions; Enzyme induction; Enzyme inhibition; Epilepsy; Review

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; CARBAMAZEPINE; CARDIOVASCULAR AGENT; CYCLOSPORIN A; CYTOCHROME P450; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; FELODIPINE; GABAPENTIN; GLUCURONOSYLTRANSFERASE; LAMOTRIGINE; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; PSYCHOTROPIC AGENT; STEROID; TIAGABINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

BLOOD TOXICITY; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SUBSTRATE; EPILEPSY; HUMAN; LIVER TOXICITY; NEUROTOXICITY; PATIENT; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; UNSPECIFIED SIDE EFFECT;

ABSORPTION; ANTICOAGULANTS; ANTICONVULSANTS; CONTRACEPTIVES, ORAL; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; ENZYME INDUCTION; ENZYME INHIBITORS; EPILEPSY; GASTROINTESTINAL TRACT; GLUCURONOSYLTRANSFERASE; HUMANS;

EID: 33644909875     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02529.x     Document Type: Review

References (81)

1. Patsalos PN Perucca E. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs Lancet Neurol 2003 2 347 56
2. Patsalos PN Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs Lancet Neurol 2003 2 473 81
3. Patsalos PN Froscher W Pisani F van Rijn C. The importance of drug interactions in epilepsy therapy Epilepsia 2002 43 365 85
4. Hachad H Ragueneau-Majlessi I Levy RH. New antiepileptic drugs: review on drug interactions Ther Drug Monit 2002 24 91 103
5. Majkowski J Bourgeois B Patsalos PN Mattson RH, eds. Antiepileptic Drugs: Combination Therapy and Interactions Cambridge Cambridge University Press 2005
6. Perucca E Hedges A Makki KA Ruprah M Wilson JF Richens A. A comparative study of the enzyme inducing properties of anticonvulsant drugs in epileptic patients Br J Clin Pharmacol 1984 18 401 10
7. Strolin Benedetti M Bani M. Metabolism-based interactions involving oral azole antifungals in humans Drug Metab Rev 1999 31 665 717
8. Anderson GD. A mechanistic approach to antiepileptic drug interactions Ann Pharmacother 1998 32 554 63
9. Spina E Perucca E Levy RH. Predictability of metabolic antiepileptic drug interactions. In Antiepileptic Drugs: Combination Therapy and Interactions Majkowski J Bourgeois B Patsalos PN Mattson RH. Cambridge Cambridge University Press 2005
10. Perucca E. Clinical implications of hepatic microsomal enzyme induction by antiepileptic drugs Pharmacol Ther 1987 33 139 44
11. Perucca E. The clinical pharmacology and therapeutic use of the new antiepileptic drugs Fund Clin Pharmacol 2001 15 405 17
12. Crawford P. Interactions between antiepileptic drugs and hormonal contraception CNS Drugs 2002 16 263 72
13. Sidhu J Bulsara S Job S Philipson R. A bidirectional pharmacokinetic interaction study of lamotrigine and the combined oral contraceptive pill in healthy subjects Epilepsia 2004 45 Suppl. 7 330
14. May TW Rambeck B Jurgens U. Serum concentrations of lamotrigine in epileptic patients: the influence of dose and comedication Ther Drug Monit 1996 18 523 31
15. Baruzzi A Albani F Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance Epilepsia 1994 35 Suppl. 3 S14 S19
16. Kim RB. Drugs as P-glycoprotein substrates, inhibitors, and inducers Drug Metab Rev 2002 34 47 54
17. Synold TW Dussault I Forman BM. The orphan nuclear receptor SXR coordinatively regulates drug metabolism and efflux Nat Med 2001 7 584 90
18. Giessmann T May K Modess C Wegner D Hecker U Zschiesche M Dazert P Grube M Schroeder E Warzok R Cascorbi I Kroemer HK Siegmund W Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans Clin Pharmacol Ther 2004 76 192 200
19. Perucca E Hebdige S Frigo GM Gatti G Lecchini S Crema A. Interaction between phenytoin and valproic acid: plasma protein binding and metabolic effects Clin Pharmacol Ther 1980 28 779 89
20. Tsanaclis LM Allen J Perucca E Routledge PA Richens A. Effect of valproate on free plasma phenytoin concentrations Br J Clin Pharmacol 1984 18 17 20
21. Benet LZ Hoener BA. Changes in plasma protein binding have little clinical relevance Clin Pharmacol Ther 2002 71 115 21
22. Perucca E Levy RH. Combination therapy and drug interactions. In Antiepileptic Drugs 5th edn Levy RH Mattson RH Meldrum BS Perucca E. Philadelphia Lippincott Williams & Wilkins 2002 96 102
23. Perucca E Gatti G Frigo GM Crema A Calzetti S Visintini D. Disposition of sodium valproate in epileptic patients Br J Clin Pharmacol 1978 5 495 9
24. May T Rambeck B. Serum concentrations of valproic acid: influence of dose and comedication Ther Drug Monit 1985 7 387 90
25. Samara EE Gustavson LE El-Shourbagy T Locke C Granneman GR Sommerville KW. Population analysis of the pharmacokinetics of tiagabine in patients with epilepsy Epilepsia 1998 39 868 73
26. Giaccone M Bartoli A Gatti G Marchiselli R Pisani F Latella MA Perucca E. Effects of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients Br J Clin Pharmacol 1996 41 575 9
27. Bartoli A Guerrini R Belmonte A Alessandri MG Gatti G Perucca E. The influence of dosage, age, and comedication on steady state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlation with clinical response Ther Drug Monit 1997 19 252 60
28. Armijo JA Bravo J Cuadrado A Herranz JL. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications Ther Drug Monit 1999 21 182 90
29. Britzi M Perucca E Soback S Levy RH Fattore C Crema F Gatti G Doose DR Maryanoff BE Bialer M Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the presence and absence of enzyme induction by carbamazepine Epilepsia 2005 47 1 7
30. Tartara A Galimberti CA Manni R Morini R Limido G Gatti G Bartoli A Strada G Perucca E The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxycarbazepine in normal subjects and in epileptic patients treated with phenobarbitone or valproic acid Br J Clin Pharmacol 1993 36 366 8
31. Ojemann LM Shastri RA Wilenski AJ Friel PN Levy RH McLean JR Buchanan RA. Comparative pharmacokinetics of zonisamide (CI-912) in epileptic patients on carbamazepine or phenytoin monotherapy Ther Drug Monit 1986 8 293 6
32. Wagner M Graves NM Marineau K Holmes GB Remmel RP Leppik IE. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate Epilepsia 1991 32 398 406
33. Khoo KC Mendels J Rothbert M Garland WA Colburn WA Min BH Lucek R Carbone JJ Boxenbaum HG Kaplan SA. I nfluence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam Clin Pharmacol Ther 1980 28 368 75
34. Sennoune S Mesdjian E Bonneton J Genton P Dravet C Roger J. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy Ther Drug Monit 1992 14 269 74
35. Christiansen J Dam M. Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy Acta Neurol Scand 1973 49 543 6
36. Perucca E Dulac O Shorvon S Tomson T. Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation CNS Drugs 2001 15 609 21
37. Battino D Croci D Granata T Bernardi G Monza G Changes in unbound and total valproic acid concentrations after replacement of carbamazepine with oxcarbazepine Ther Drug Monit 1992 14 376 9
38. Yuen AWC Land G Weatherley B Peck AW. Sodium valproate inhibits lamotrigine metabolism Br J Clin Pharmacol 1992 33 511 3
39. Binnie CD Van Emde Boas W Kasteleijn Nolste Trenite DG De Korte RA Meijer JWA Meinardi H Miller AA Overweg J Peck AW Van Wieringeen A Yuen WC. Acute effects of lamotrigine (BW430C) in persons with epilepsy Epilepsia 1986 27 248 54
40. Gidal BE Anderson GD Rutecki PR Shaw R Lanning A. Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy Epilepsy Res 2000 42 23 31
41. Kapetanovic IM Kupferberg HJ Porter RJ Theodore W Schulman E Penry JK. Mechanism of valproate-phenobarbital interaction in epileptic patients Clin Pharmacol Ther 1981 29 480 6
42. Barcs G Walker EB Elger CE Scaramelli A Stefan H Sturm Y Moore A Flesch G Kramer L D'Souza J. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy Epilepsia 2000 41 1597 607
43. Bialer M Doose DR Murthy B Curtin C Wang SS Twyman RE Schwabe S Pharmacokinetic interactions of topiramate Clin Pharmacokinet 2004 12 763 80
44. Pisani F Fazio A Oteri G Ruello C Gitto C Russo F Perucca E. Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients Epilepsia 1986 27 548 52
45. Pisani F Oteri G Russo MF Di Perri R Perucca E Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction Epilepsia 1999 40 1141 6
46. Rowan AJ Meijer JWA de Beer-Pawlikowski N van der Geest P Meinardi H. Valproate-ethosuximide combination therapy for refractory absence seizures Arch Neurol 1983 40 797 802
47. Besag FMC Berry DJ Pool F Newbery JE Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia 1998 39 183 7
48. Sabers A Ohman I Christensen J Tomson T. Oral contraceptives reduce lamotrigine plasma levels Neurology 2003 61 570 1
49. Sabers A Buchholt JM Uldall P Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives Epilepsy Res 2001 47 151 4
50. Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feeding Neurology 1982 32 570 2
51. Worden JP Jr. Wood CA Jr. Workman CH. Phenytoin and nasogastric feedings Neurology 1984 34 132
52. Vecht CJ Wagner GL Wilms EB. Interactions between antiepileptic and chemotherapeutic drugs Lancet Neurol 2003 2 404 9
53. De Turck BJ Diltoer MW Corneli PJ Cornelis PJ Maes V Spapen HD Camu F Huyghens LP. Lowering of plasma valproic acid concentrations during concomitant therapy with meropenem and amikacin J Antimicrob Chemother 1998 42 563 4
54. Sander JW Perucca E. Epilepsy and comorbidity: infections and antimicrobials usage in relation to epilepsy management Acta Neurol Scand 2003 108 Suppl. 180 16 22
55. Von Moltke LL Greenblatt DJ Schmider J Wright CE Harmatz J Schader RI. In vitro approaches to predicting drug interactions in vivo Biochem Pharmacol 1998 55 113 22
56. Pauwels O. Factors contributing to carbamazepine-macrolide interactions Pharmacol Res 2002 45 291 8
57. Van Rosensteil NA Adam D. Macrolides antibacterials. Drug interactions of clinical significance Drug Safety 1995 13 105 22
58. Ducharme MP Slaughter RL Warbasse LH Chandrasekar PH Van de Velde V Mannens G Edwards DJ. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than ten-fold by phenytoin Clin Pharmacol Ther 1995 58 617 24
59. Bittencourt PRM Gracia CM Martins R Fernandes AG Diekmann HW Jung W. Phenytoin and carbamazepine decrease oral bioavailability or praziquantel Neurology 1992 42 492 6
60. Romanelli F Jennings HR Nath A Ryan M Berger J. Therapeutic dilemma: the use of anticonvulsants in HIV-positive individuals Neurology 2000 54 1404 7
61. Hugen PW Burger DM Brinkman K Ter Hofstede HJ Schuurman R Koopmans PP Hekster YA. Carbamazepine-indinavir interaction causes antiretroviral therapy failure Ann Pharmacother 2000 34 465 70
62. Liedtke MD Lockart SM Rathbun RC. Anticonvulsant and antiretroviral interactions Ann Pharmacother 2004 38 482 9
63. Flockart DA Tanus-Santos JE. Implications of cytochrome P450 interactions when prescribing medication for hypertension Arch Intern Med 2002 162 405 12
64. Tartara A Galimberti CA Manni R Parietti L Zucca C Baasch H Caresia L Muck W Barzaghi N Gatti G Perucca E. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine bioavailability in epileptic patients Br J Clin Pharmacol 1991 32 335 40
65. Michelucci R Cipolla G Passarelli D Gatti G Ochan M Heinig R Tassinari CA Perucca E. Reduced plasma nisoldipine concentrations in phenytoin-treated patients with epilepsy Epilepsia 1996 37 1107 10
66. Spina E Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs Epilepsia 2002 43 Suppl. 2 37 44
67. DeToledo JC Haddad H Ramsey SE. Status epilepticus associated with the combination of valproic acid and clomipramine Ther Drug Monit 1997 19 71 3
68. Soriano SG Martyn JA. Antiepileptic-induced resistance to neuromuscular blockers: mechanisms and clinical significance Clin Pharmacokinet 2004 43 71 81
69. Krauss GL Brandt J Campbell M Plate C Summerfield M. Antiepileptic medications and oral contraceptive interactions. A national survey of neurologists and obstetricians Neurology 1996 46 1534 9
70. Crawford P Lee P. Gender difference in the management of epilepsy - what women are hearing Seizure 1999 8 135 9
71. Doose DR Wang SS Padmanabham M Schwabe S Jacobs D Bialer M. The effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethisterone and ethinyl estradiol in healthy obese and nonobese female subjects Epilepsia 2003 44 540 9
72. Rosenfeld WE Doose DR Walker SA Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethisterone and ethinyl estradiol in patients with epilepsy Epilepsia 1997 38 317 23
73. Crawford P Chadwick DJ Maryin C Tjia J Back DJ Orme M. The interaction of phenytoin and carbamazepine with combined oral contraceptive steroids Br J Clin Pharmacol 1990 30 892 6
74. Bounds B Guillebaud. Observational series on women using the contraceptive Mirena concurrently with anti-epileptic and other enzyme-inducing drugs J Fam Plann Reprod Health Care 2002 28 78 80
75. Herzog AG Farina EL Blum AS. Serum valproate levels with oral contraceptive use Epilepsia 2005 46 970 1
76. Harder S Thurmann P. Clinically important drug interactions with anticoagulants. An update Clin Pharmacokin 1996 30 416 44
77. Cropp JS Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for patient management Pharmacotherapy 1997 17 917 28
78. Breckenridge A. Drug interactions with oral anticoagulants BMJ 1974 2 397 400
79. McDonald MG Robinson DS. Clinical observations of possible barbiturate interference with anticoagulation J Am Med Ass 1968 204 95 9
80. Hassan Y Awaisu A Aziz NA Ismail O. The complexity of achieving anticoagulation control in the face of warfarin-phenytoin interaction: an Asian case report Pharm World Sci 2005 27 16 9
81. Stephen LJ. Drug treatment of epilepsy in elderly people: focus on valproic acid Drugs Aging 2003 20 141 52